PharmaCyte (PMCB) Director Michael Abecassis Cancels Award

What Happened

• Michael M. Abecassis, a director of PharmaCyte Biotech, amended a Form 4 to report that a previously reported grant was made in error and has been cancelled. The original entry shows a derivative transaction coded "J" for 0 shares @ N/A (no value); the amendment clarifies no award was issued.

Key Details

• Transaction date reported: 2026-03-31 (amended filing date: 2026-07-17)
• Transaction type/code: Other acquisition/disposition (J) — derivative; 0 shares, price N/A
• Shares owned after transaction: no change reported (no shares issued from this entry)
• Footnote: F1 — "The reported grant was made in error and has been cancelled."
• Filing status: This is an amended Form 4 filed months after the original report (i.e., the amendment was submitted after the reported transaction date)

Context

• This filing does not reflect an actual purchase, sale, exercise, or receipt of equity; it corrects a previously reported grant. For retail investors, corrections like this mean there was no insider buy/sell signal associated with the original (erroneous) entry.